Crossref
Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics
JAMA · 26.05.2026 · 335 (20) · 1739
DOI: 10.1001/jama.2026.6177 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 26.05.2026. Verfasst von Samantha Anderer. Beteiligte Einrichtung: Staff Writer, Medical News, JAMA.
Abstract (Originalsprache)
This Medical News article discusses findings that genetic variants may affect patients’ responses to glucagon-like peptide-1 receptor agonists such as semaglutide and tirzepatide.
Autor:innen und Institutionen
- Staff Writer, Medical News, JAMA.
Zitieren
APA
Anderer, S. (2026). Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics. JAMA, 335(20), 1739. https://doi.org/10.1001/jama.2026.6177
Vancouver
Anderer S. Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics. JAMA. 2026;335(20):1739. doi:10.1001/jama.2026.6177
BibTeX
@article{Anderer2026,
author = {Anderer, Samantha},
title = {Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics},
journal = {JAMA},
year = {2026},
volume = {335},
number = {20},
pages = {1739},
doi = {10.1001/jama.2026.6177}
}
EUVIMED